-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) once-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.This Phase III clinical trial is a randomized, double-blind, pla ...